Modelled DT Structure
Method: homology modeling
Template PDB: 3F1R_A; 3WIQ_A; 6EI3_A
Identity: 63.636% ; 21.818% ; 23.952%
Minimized Score: -828.827 kcal/mol
Detail: Structure Info
Drug Transporter (DT) Information
| General Information of DT | |||||
|---|---|---|---|---|---|
| DT ID | DTD0099 | ||||
| Gene Name | SLC15A4 | ||||
| Protein Name | Peptide transporter 4 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| TCDB ID | |||||
| 3D Structure |
|
||||
| Synonyms | FP12591; PHT1; PTR4; Peptide/histidine transporter 1; SLC15A4; Solute carrier family 15 member 4; hPHT1 | ||||
| DT Family | Proton-Dependent Oligopeptide Transporter (POT/PTR) Family ; | ||||
| Tissue Specificity | Highly expressed in skeletal muscle.Moderately expressed in kidney, liver, and heart. Weakly expressedin colon and brain. Expressed in low levels throughout thegastrointestinal tract and in Caco-2 cells. Expressed in retinalfragment epithelium (RPE) and neural retina. Expressed in smallintestine, stomach, duodenum, jejunum, ileum and colon. | ||||
| Function | This proton oligopeptide cotransporter mediates the transport of free histidine and certain di- and tripeptides. | ||||
| Endogenous Substrate(s) | Peptides; Histidine | ||||
| Variability Data of This Drug Transporter (DT) | |||||
|
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
|
(β) Post-translational Modification of This DT |
|||||
|
(γ) Transcriptional Regulation of This DT |
|||||
|
(δ) Epigenetic Regulation of This DT |
|||||
|
General Variability Data of This DT (VARIDT 1.0) |
|||||
|
(α) Genetic Polymorphisms of This DT |
|||||
|
(β) Disease-specific Protein Abundances of This DT |
|||||
|
(γ) Species- and Tissue-specific DT Abundances |
|||||
| Molecular Transporting Profile of This DT | |||||
|
Full List of Drug(s) Transported by This DT |
|||||
|
Clinical Trial Drug |
Click to Show/Hide the Full List of Drug: 1 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
|
L-histidine
|
Phase 2/3 | Drug Info | HARS Syndrome | N.A. | [1] |
|
Drug-DT Affinity Assessed by Cell Line |
|||||
|
Clinical Trial Drug |
Click to Show/Hide the Full List of Drug: 1 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Cell Line | Affinity | Ref |
| L-histidine | Phase 2/3 | Drug Info | Xenopus laevis oocytes-PTR4 | Km = 16.3 microM | [1] |
|
Withdrawn, Discontinued or Preclinical Drug |
Click to Show/Hide the Full List of Drug: 1 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Cell Line | Affinity | Ref |
| Peptides | Investigative | Drug Info | Xenopus laevis oocytes-PTR4 | Km = 1.69 microM | [1] |
| References | |||||
| 1 | Functional Characterization of Human Peptide/Histidine Transporter 1 in Stably Transfected MDCK Cells. Mol Pharm. 2018 Feb 5;15(2):385-393. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.